Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1040-1046

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. R.
Right arrow Articles by Cooke, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J. R.
Right arrow Articles by Cooke, J. P.
Related Collections
Right arrow Mechanism of atherosclerosis/growth factors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1040.)
© 2000 American Heart Association, Inc.


Vascular Biology

Asymmetric Dimethylarginine Increases Mononuclear Cell Adhesiveness in Hypercholesterolemic Humans

Jason R. Chan; Rainer H. Böger; Stefanie M. Bode-Böger; Oranee Tangphao; Philip S. Tsao; Terrence F. Blaschke; John P. Cooke

From the Section of Vascular Medicine, Division of Cardiovascular Medicine, and the Department of Clinical Pharmacology (O.T., T.F.B.), Stanford University School of Medicine, Stanford, Calif.

Correspondence to John P. Cooke, MD, PhD, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305-5406. E-mail john.cooke{at}stanford.edu

Abstract—Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is elevated in hypercholesterolemia. This study was designed to determine the role of ADMA in the increased mononuclear cell adhesiveness observed in human hypercholesterolemia. In patient studies, plasma ADMA levels were determined by high-performance liquid chromatography. Functional mononuclear leukocyte adhesion assays were performed in parallel, and flow cytometry was used to characterize bound monocytes and T lymphocytes. Hypercholesterolemic patients were then placed on an oral L-arginine regimen of 14 or 21 g/d and studied over 12 weeks. In cell culture studies, bovine aortic endothelial cells were incubated with varied concentrations of ADMA. Monocytoid cells were cocultured with these bovine aortic endothelial cells, and their adhesiveness was assessed by use of a binding assay. Flow cytometry was used to quantify adhesion molecule expression. Plasma ADMA levels and adhesiveness of mononuclear cells (specifically, monocytes and T lymphocytes) were elevated in hypercholesterolemic patients. Adhesiveness was inversely correlated with the plasma L-arginine/ADMA ratio. Oral administration of L-arginine normalized plasma L-arginine/ADMA ratios and attenuated monocyte and T-lymphocyte adhesiveness. ADMA had no direct effect on the adhesiveness of mononuclear cells. However, monocytes became hyperadhesive when cocultured with ADMA-exposed endothelial cells. In human hypercholesterolemia, the plasma L-arginine/ADMA ratio is inversely correlated with mononuclear cell adhesiveness. Restoration of the L-arginine/ADMA ratio to control levels normalizes mononuclear cell adhesiveness. Our studies suggest that the elaboration of endothelium-derived nitric oxide affects the behavior of circulating T lymphocytes and monocytes.


Key Words: L-arginine • atherosclerosis • monocytes • endothelium • T lymphocytes




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Desai, Y. Zhao, and J. S. Warren
Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1513 - 1520.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. J. Nicholls, Z. Wang, R. Koeth, B. Levison, B. DelFraino, V. Dzavik, O. W. Griffith, D. Hathaway, J. A. Panza, S. E. Nissen, et al.
Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction
Circulation, November 13, 2007; 116(20): 2315 - 2324.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. T. Kielstein, F. Donnerstag, S. Gasper, J. Menne, D. Fliser, A. Kielstein, J. Martens-Lobenhoffer, F. Scalera, S. M. Bode-Boger, and J. Cooke
Response to Letter by Tsuda
Stroke, December 1, 2006; 37(12): 2871 - 2871.
[Full Text] [PDF]


Home page
CirculationHome page
M. Tanaka, K. Sydow, F. Gunawan, J. Jacobi, P. S. Tsao, R. C. Robbins, and J. P. Cooke
Dimethylarginine Dimethylaminohydrolase Overexpression Suppresses Graft Coronary Artery Disease
Circulation, September 13, 2005; 112(11): 1549 - 1556.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. H Boger
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
Vascular Medicine, July 1, 2005; 10(1_suppl): S19 - S25.
[Abstract] [PDF]


Home page
Vasc MedHome page
R. H Boger
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
Vascular Medicine, May 1, 2005; 10(2_suppl): S19 - S25.
[Abstract] [PDF]


Home page
J. Nutr.Home page
S. G. West, A. Likos-Krick, P. Brown, and F. Mariotti
Oral L-Arginine Improves Hemodynamic Responses to Stress and Reduces Plasma Homocysteine in Hypercholesterolemic Men
J. Nutr., February 1, 2005; 135(2): 212 - 217.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. V. Smirnova, M. Kajstura, T. Sawamura, and M. S. Goligorsky
Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H782 - H790.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. P. Cooke
Asymmetrical Dimethylarginine: The Uber Marker?
Circulation, April 20, 2004; 109(15): 1813 - 1818.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. H Boger
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
Cardiovasc Res, October 1, 2003; 59(4): 824 - 833.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Niebauer, A. J. Maxwell, P. S. Lin, D. Wang, P. S. Tsao, and J. P. Cooke
NOS inhibition accelerates atherogenesis: reversal by exercise
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H535 - H540.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Sydow, E. Schwedhelm, N. Arakawa, S. M. Bode-Boger, D. Tsikas, B. Hornig, J. C. Frolich, and R. H. Boger
ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins
Cardiovasc Res, January 1, 2003; 57(1): 244 - 252.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. J. Cardounel and J. L. Zweier
Endogenous Methylarginines Regulate Neuronal Nitric-oxide Synthase and Prevent Excitotoxic Injury
J. Biol. Chem., September 6, 2002; 277(37): 33995 - 34002.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. C. Stuhlinger, F. Abbasi, J. W. Chu, C. Lamendola, T. L. McLaughlin, J. P. Cooke, G. M. Reaven, and P. S. Tsao
Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor
JAMA, March 20, 2002; 287(11): 1420 - 1426.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. P. Cooke
Does ADMA Cause Endothelial Dysfunction?
Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2032 - 2037.
[Abstract] [Full Text] [PDF]